Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Presented here is ovarian tissue oocyte-in vitro maturation (OTO-IVM), an accessible technique within a medical assisted reproduction (MAR) laboratory offering realistic additional fertility preservation options to patients who need ovarian tissue cryopreservation.

Abstract

Mature oocyte vitrification is the standard of care to preserve fertility in women at risk of infertility. However, ovarian tissue cryopreservation (OTC) is still the only option to preserve fertility in women who need to start gonadotoxic treatment urgently or in prepubertal children. During ovarian cortex preparation for cryopreservation, medullar tissue is removed. Growing antral follicles reside at the border of the cortex-medullar interface of the ovary and are broken during this process, releasing their cumulus-oocyte complex (COC). By thoroughly inspecting the medium and fragmented medullar tissue, these immature cumulus-oocyte complexes can be identified without interfering with the OTC procedure. The ovarian tissue-derived immature oocytes can be successfully matured in vitro, creating an additional source of gametes for fertility preservation. If OTC is performed within or near a medical assisted reproduction laboratory, all necessary in vitro maturation (IVM) and oocyte vitrification tools can be at hand. Furthermore, upon remission and child wish, the patient has multiple options for fertility restoration: ovarian tissue transplantation or embryo transfer after the insemination of vitrified/warmed oocytes. Hence, ovarian tissue oocyte-in vitro maturation (OTO-IVM) can be a valuable adjunct fertility preservation technique.

Introduction

Fertility preservation (FP) options for women planned for gonadotoxic treatment, sex-reassignment therapy, or women who have a genetic predisposition for premature ovarian failure, depend on the health and age of the patient, available timeframe, type of treatment, patient's preference, and FP procedures available at the fertility center of choice. Vitrification of mature oocytes obtained after ovarian stimulation with gonadotropins and oocyte retrieval in a medical assisted reproduction (MAR) laboratory cycle is considered the preferred option for FP1,2. However, for prepubertal girls, women in whom the u....

Protocol

The present study on OTO-IVM has been approved by the local Ethical Committee of UZ-Brussels (addendum of project 2008/068 and project 2022/303). All patients signed written informed consent. Each patient was individually assessed by a reproductive medicine specialist physician, navigator nurse, and the referring oncologist to compose the optimal FP treatment plan, taking into account the patient's preferences14. In short, patients eligible for OTC are in urgent need of FP and are less than 36.......

Representative Results

Over the past decade, 98 patients undergoing oophorectomy or ovarian biopsy for OTC were also offered OTO-IVM. The results presented here are an update of the clinical program as published before7,13. Immature oocytes obtained during ovarian tissue processing were matured in vitro predominantly for 30 h. However, a more flexible maturation time was allowed for practical reasons or because of low maturation, ranging from 28-42 h. Patients opted predominan.......

Discussion

The priority of the FP procedure is always to manipulate and freeze the ovarian cortex according to the standard operating protocol that has been validated in the clinic. A drawback in FP is the absence of a standard protocol available in the published literature regarding OTC and OTO-IVM. It is difficult to assess the efficiency and validity of the techniques and adaptations since there is a large time gap between freezing/vitrification and thawing/warming in a clinical setting. If changes to the OTC protocol are made t.......

Acknowledgements

This work was conducted at the IVF laboratory of Brussels IVF, Universitair Ziekenhuis of VUB, Brussels. The authors would like to thank all Brussels IVF laboratory team members for their high skills, accuracy, and flexibility needed to establish a fertility preservation unit within a MAR laboratory.

....

Materials

NameCompanyCatalog NumberComments
1000 µL filter tipsEppendorf/VWR International613-6780COC search
Benchtop CoolerFisher Scientific15-350-54Benchtop Cooler lid is used to prepare the tissue, Benchtop Cooler tube holder to keep cryovials with freezing medium cooled
Corning Cell culture dish, non-treated, 100 mmCorning/VWR International430591Dish for ovarian tissue preparation
CryoSure-DMSOWAK Chemicals0482Cryoprotectant for ovarian tissue cryopreservation
CumulaseOrigio/CooperSurgical16125000Arecombinant human hyaluronidase enzyme for cumulus cell removal after IVM
Decontamination spray: SuproxMedipure LTDMP016Desinfectant solution for aseptic handling with bactericide and sporicide action
Disposable scalpelsSwann-Morton0511Ovarian tissue preparation
Falcon 14 mL Round Bottom Polystyrene Test Tube, with Snap Cap, SterileFalcon/VWR InternationalBDAA352057Medium container 
Falcon Cell strainer 70 µmFalcon/VWR International352350Filter for elimination of red blood cell contamination and COC search
Freeze control Ampoule Cryochamber and Temperature ControllerCryologicCL-8800i   CC60ASSlow freezing machine
FSH: Menopur 75 IUFerringBE197504Follicle Stimulating Hormone : Supplement for IVM medium
Handling pipette 290-310 µmVitrolife15538COC search: gentle transfer of COC without damaging oocyte-cumulus cell connectivity
hCG: Brevactid 5000 IEFerring5008001036Human Chorionic Gonadotropin : Supplement for IVM medium
High security tubeCryoBioSystem022252cryovial, heat-sealed for safe cryostorage
HSA-solutionVitrolife10064Human serum Albumin: supplement for IVM medium
Leibovitz's L-15 mediumLife Technologies Europe31415-029Handling medium for ovarian tissue preparation
MediCult IVM systemOrigio/CooperSurgical82214010medium for IVM containing both LAG and IVM medium. IVM medium needs to be supplemented as detailed in the protocol
METZENBAUM fino scissors 140 mmChirurgical MaintenanceVIZ08280314Medium size scissors for initial medulla removal
Nunc 4-well dishes for IVFNunc/VWR International144444COC collection during COC search and IVM culture
Nunc Invitro fertilization Petri Dish with Vented Lid, 60 mm, Non-Pyrogenic, SterileThermo Scientific/VWRNUNC150270Dish for COC search
Oocyte handling medium : Flushing Medium with heparinOrigio/CooperSurgical10765060Search medium for COC search
OvoilVitrolife10029oil for IVM culture
Penicillin/Streptomicin mixLife Technologies Europe15140-148Supplement for OTC handling medium
Scissors, curved, 150 mm long, 20 mm bladeChirurgical MaintenanceVIREBST999-SCSmall size scissors for residual medulla removal

References

  1. Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertility and Sterility. 112 (6), 1022-1033 (2019).
  2. Anderson, R. A., et al.

Explore More Articles

Ovarian Tissue CryopreservationOocyte VitrificationFertility PreservationIn Vitro MaturationCumulus oocyte ComplexFertility RestorationOvarian CortexMedullary TissueAntral FolliclesGonadotoxic Treatment

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved